AVITAR, INC. to present at the National Law Enforcement and Corrections Technology Center Conference on Innovative Technologies for Community Corrections (Denver, CO, June 1-2, 2000).

May 30, 2000

CANTON, MA, May 30, 2000–Avitar, Inc. (AMEX:AVR) announced today that Charles Plate, Ph.D., Director of Research and Development, will be a featured speaker at the Innovative Technologies for Community Corrections Conference sponsored by the National Law Enforcement and Corrections Technology Center (NLECTC), in Denver, Colorado, June 1-2, 2000. Dr. Plate will deliver his presentation, "Oral Fluid Point-of-Contact Drugs of Abuse Test."

Dr. Plate will present Avitar’s product, ORALscreen™ 4 (TCOM) and its performance characteristics at the NLECTC conference. He will discuss the advantages of oral fluid testing for drugs of abuse with an on-site product versus urine collection. He will focus on the procedure for oral fluid testing for key drugs of abuse as well as performance data.

Dr. Plate’s data has been obtained from in-house studies as well as field trials, including results from methadone clinics and probation sites. In general, findings are similar to urine testing for the first few days after drug use. Detecting marijuana in oral fluid is most useful as an indicator of being "under the influence" because of oral fluid’s unique ability to detect marijuana immediately or within hours of use.

"We are pleased there is an opportunity for Chuck to speak about our non-invasive, rapid oral fluid-based drugs of abuse test to help educate the correctional community," said Peter Phildius, Chairman and Chief Executive Officer. "Supplying information about our oral fluid-based drugs of abuse test and demonstrating its use will help agents of law enforcement better understand the simplicity and immediacy of our oral fluid technology. Moreover, it will help them recognize applications for its use within the probation, parole and punitive environments."

Dr. Plate has over twenty years of experience as an academic and commercial scientist. Prior to joining Avitar, he managed academic collaborations that developed assays for cancer, infectious diseases, immunology and sexually transmitted diseases for Abbott Laboratories’ Diagnostics Division. Dr. Plate’s experience ranges from early prototype development to in-line product improvements.

Dr. Plate has held the position of Assistant Professor at Northwestern University Medical and Dental Schools, and Research Associate at Massachusetts Institute of Technology. After receiving his Ph.D. in Biochemistry from Duke University, Durham, NC, Dr. Plate completed an American Cancer Society postdoctoral fellowship with nobel laureate S.E. Luria at MIT.

ORALscreen is the world’s first oral fluid point-of-contact drugs of abuse testing system. Avitar’s simple, reliable and portable drug test creates new investigative opportunities by allowing earlier, less invasive collection of toxicological evidence of marijuana (THC), cocaine, opiates and methamphetamine.

The Rocky Mountain Region of the National Law Enforcement and Corrections Technology Center is the host of the up coming conference that will explore applications of innovative technologies in community corrections, practical applications of the technology and live demonstrations from leading developers and vendors. Scheduled speakers will also discuss the practical application of technology in the New York City Department of Probation and the New Mexico Department of Corrections Probation and Parole Division. The admission-free, two-day event will be held at the Embassy Suites Southeast in Denver, Colorado.

Avitar, Inc. (AMEX:AVR) headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The Company markets a unique portfolio of substance abuse testing products and services that include ORALscreen^TM, the world’s first rapid point-of-contact oral fluid test for drugs of abuse, HAIRscreen^TM, a laboratory-based test for long term drug abuse using hair, and several other specialized tests for drugs of abuse. Avitar also markets an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices. For more information, see Avitar’s website at avitarinc.com.

This release forward looking statements that are subject to risks and uncertainties, including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission.